Sandu Pharmaceuticals informs about board meeting

Sandu Pharmaceuticals Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524703 | NSE:

06 Jul 2026 Evaluate

Sandu Pharmaceuticals has informed that a Meeting of the Board of Directors of the Company will be held on Saturday, the 11th day of July 2026 at 04:00 pm at the Corporate Office of the Company at Sandu Pharmaceuticals, Sandu Nagar, D K Sandu Marg, Chembur, Mumbai 400071 to consider the following 1. To place on record the demise of Shri Umesh B. Sandu (DIN:01132141), Managing Director of the Company, on 19th June, 2026, and to record the Board's appreciation for his invaluable contribution to the Company. 2. To consider and approve the appointment of a Managing Director of the Company pursuant to the demise of the erstwhile Managing Director, Late Shri Umesh B. Sandu, subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals as may be required. 3. To consider and approve the reconstitution of the Committees of the Board. 4. To consider and approve the appointment of an Additional Director in the capacity of an Independent Director (Non-Executive) on the Board of the Company, subject to the approval of the shareholders of the Company and such other statutory and regulatory approvals, if any, as may be required. This notice is being submitted pursuant to Regulation 29 of the Securities & Exchange Board of India (Listing Regulations and Disclosure Requirements) Regulation 2015. In Compliance with the Company’s Code of Conduct for prevention of Insider Trading devised as per the SEBI (Prohibition of Insider Trading) the company has informed that the trading window for dealing in the Securities of the Company has been closed for the Company’s Directors/Officer and designated employees of the Company from the opening of Trading hours on Wednesday, 1st day of July 2026 till 48 hours after announcement of financial results to public for the Quarter ended 30th June 2026 in compliances with the code of conduct for prevention of Insider Trading Regulation 2015.

The above information is a part of company’s filings submitted to BSE.

Sandu Pharmaceutical Share Price

40.66 -1.26 (-3.01%)

07-Jul-2026 16:59 View Price Chart

Peers

Company Name	CMP
Sun Pharma. Inds.	1903.00
Dr. Reddys Labs.	1353.75
Cipla	1452.35
Zydus Lifesciences	1152.90
Lupin	2489.85
View more..

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045
Compliance officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com Telephone: +91 98609 19463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com Telephone: +91 91758 99463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.